Background Low vitamin D levels can be associated with albuminuria, and vitamin D analogs are effective anti-proteinuric agents. The aim of this study was to investigate differences in vitamin D levels between those with micro- and those with macroalbuminuria, and to determine whether low dose cholecalciferol increases vitamin D levels and ameliorates albuminuria. Methods Two studies were performed in which 25-OH vitamin D3 (25(OH)D3) concentrations were determined by electrochemiluminescence immunoassay: 1) a cross-sectional study of patients with type 2 diabetes mellitus (T2DM) (n = 481) and healthy controls (n = 78); and 2) a longitudinal study of T2DM patients with albuminuria treated with conventional doses, 800 IU, of cholecalciferol for 6 months (n = 22), and a control group (n = 24). Results 1) Cross-sectional study: Compared to controls and T2DM patients with normoalbuminuria, serum 25(OH)D3 concentrations were significantly lower in patients with macro-albuminuria, but not in those with micro-albuminuria. Serum 25(OH)D3 levels were independently correlated with microalbuminuria. 2) Longitudinal study: Cholecalciferol significantly decreased microalbuminuria in the early stages of treatment, in conjunction with an increase in serum 25(OH)D3 levels. Conclusions Low vitamin D levels are common in type 2 diabetic patients with albuminuria, particularly in patients with macroalbuminuria, but not in those with microalbuminuria. Conventional doses of cholecalciferol may have antiproteinuric effects on Chinese type 2 diabetic patients with nephropathy.
References
[1]
Yang W, Lu J, Weng J, Jia W, Ji L, et al. (2010) Prevalence of diabetes among men and women in China.N Engl J Med. 362: 1090–1101.
[2]
Locatelli F, Pozzoni P, Del Vecchio L (2004) Renal replacement therapy in patients with diabetes and end-stage renal disease.J Am Soc Nephrol. 15 Suppl 1: S25–29.
[3]
Ruggenenti P, Perna A, Remuzzi G (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.Kidney Int. 63: 2254–2261.
[4]
de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS (2007) 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III) Am J Kidney Dis. 50: 69–77.
[5]
Fiscella KA, Winters PC, Ogedegbe G (2011) Vitamin D and racial disparity in albuminuria: NHANES 2001–2006.Am J Hypertens. 24: 1114–1120.
[6]
de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, et al. (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.Lancet. 376: 1543–1551.
[7]
Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, et al. (2011) Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.Kidney Int. 80: 851–860.
[8]
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.Ann Intern Med 130: 461–470.
[9]
Wang Y, Zhou J, Minto AW, Hack BK, Alexander JJ, et al. (2006) Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy.Kidney Int. 70: 882–891.
[10]
Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, et al. (2007) 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells.Kidney Int. 72: 193–201.
[11]
Zhang Z, Sun L, Wang Y, Ning G, Minto AW, et al. (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy.Kidney Int. 73: 163–171.
[12]
Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, et al. (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.Proc Natl Acad Sci U S A. 105: 15896–15901.
[13]
Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD (2010) Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD.J Am Soc Nephrol. 21: 353–361.
[14]
Helvig CF, Cuerrier D, Hosfield CM, Ireland B, Kharebov AZ, et al. (2010) Dysregulation of renal vitamin D metabolism in the uremic rat.Kidney Int. 78: 463–472.
[15]
Chun RF.(2012) New perspectives on the vitamin D binding protein.Cell Biochem Funct.
[16]
Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, et al. (2004) Nephropathy in diabetes.Diabetes Care. 27 Suppl 1: S79–83.
[17]
Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, et al. (2009) 25-hydroxyvitamin D levels, race, and the progression of kidney disease.J Am Soc Nephrol. 20: 2631–2639.
[18]
Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, et al. (2007) Low vitamin D status despite abundant sun exposure.J Clin Endocrinol Metab. 92: 2130–2135.
